Payment overview · 2025
General Payments
$216.34
9 reported records · 7 companies
Healthcare provider profile · identity verified
Joseph David Barker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LINVILLE, NC · NPI 1194704817
Verified facts
What the public records show
CMS Open Payments records show Joseph David Barker, M.D. received $216.34 in general payments during 2025 across 9 reported records.
Stryker Corporation accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $72.75 | 33.6% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $49.00 | 22.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.37 | 13.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.84 | 8.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.81 | 8.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.64 | 6.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.93 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $216.34 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAKO Normalized: mako |
Device | Stryker Corporation | $72.75 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $49.00 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 415 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 353 | 95 |
| Eliquis | Apixaban | 309 | 41 |
| Prednisone | Prednisone | 260 | 116 |
| Furosemide | Furosemide | 244 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 233 | 51 |
| Lisinopril | Lisinopril | 214 | 60 |
| Trazodone Hcl | Trazodone Hcl | 196 | 26 |
| Lorazepam | Lorazepam | 195 | 30 |
| Potassium Chloride | Potassium Chloride | 193 | 55 |
| Famotidine | Famotidine | 191 | 50 |
| Losartan Potassium | Losartan Potassium | 186 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 55 |
| Azithromycin | Azithromycin | 172 | 88 |
| Gabapentin | Gabapentin | 165 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 43 |
| Omeprazole | Omeprazole | 161 | 37 |
| Tramadol Hcl | Tramadol Hcl | 153 | 30 |
| Cefdinir | Cefdinir | 151 | 77 |
| Metformin Hcl | Metformin Hcl | 139 | 41 |
| Mirtazapine | Mirtazapine | 132 | 24 |
| Alprazolam | Alprazolam | 118 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 32 |
| Sertraline Hcl | Sertraline Hcl | 106 | 13 |
| Montelukast Sodium | Montelukast Sodium | 105 | 19 |
| Pregabalin | Pregabalin | 104 | 24 |
| Cephalexin | Cephalexin | 100 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 14 |
| Donepezil Hcl | Donepezil Hcl | 85 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 19 |
| Meloxicam | Meloxicam | 83 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 27 |
| Diazepam | Diazepam | 71 | 12 |
| Carvedilol | Carvedilol | 70 | 15 |
| Divalproex Sodium | Divalproex Sodium | 67 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 21 |
| Atenolol | Atenolol | 65 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 13 |
| Baclofen | Baclofen | 62 | suppressed |
| Clonazepam | Clonazepam | 60 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 16 |
| Ondansetron Odt | Ondansetron | 56 | 24 |
| Ozempic | Semaglutide | 55 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 54 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | suppressed |
| Nystatin | Nystatin | 53 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 31 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 41 | suppressed |
| Allopurinol | Allopurinol | 39 | 15 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 11 |
| Simvastatin | Simvastatin | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 25 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 21 |
| Temazepam | Temazepam | 28 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Estradiol | Estradiol | 24 | 11 |
| Linzess | Linaclotide | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 11 | suppressed |
| Striverdi Respimat | Olodaterol Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $216.34 · 9 records | Stryker Corporation | LOREEV XR, MAKO, MOUNJARO, Ozempic, REXULTI, Rybelsus, UZEDY, VOQUEZNA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error